Impact of genetic variation in the SLCO1B1 gene on statin efficacy in low-density lipoprotein cholesterol-lowering therapy

Pharmacogenomics. 2011 Feb;12(2):137-9. doi: 10.2217/pgs.10.214.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alleles
  • Cholesterol, LDL / blood*
  • Dose-Response Relationship, Drug
  • Dyslipidemias / drug therapy
  • Genetic Variation / genetics
  • Haplotypes / genetics
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Liver-Specific Organic Anion Transporter 1
  • Organic Anion Transporters / genetics*
  • Precision Medicine

Substances

  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Liver-Specific Organic Anion Transporter 1
  • Organic Anion Transporters
  • SLCO1B1 protein, human